抗逆转录病毒治疗期间的残余病毒复制可增强感染后早期接受治疗的受试者中1型人类免疫缺陷病毒特异性CD8 + T细胞反应。
Residual viral replication during antiretroviral therapy boosts human immunodeficiency virus type 1-specific CD8+ T-cell responses in subjects treated early after infection.
作者信息
Ortiz Gabriel M, Hu Jennifer, Goldwitz Joshua A, Chandwani Rohit, Larsson Marie, Bhardwaj Nina, Bonhoeffer Sebastian, Ramratnam Bharat, Zhang Linqi, Markowitz Martin M, Nixon Douglas F
机构信息
Aaron Diamond AIDS Research Center, The Rockefeller University, New York, New York 10016, USA.
出版信息
J Virol. 2002 Jan;76(1):411-5. doi: 10.1128/jvi.76.1.411-415.2002.
Abstract
Human immunodeficiency virus type 1 (HIV-1)-infected subjects treated early after infection have preserved HIV-1-specific CD4+ T-cell function. We studied the effect of highly active antiretroviral therapy (HAART) on the frequency of HIV-1-specific CD8+ T cells in patients treated during early (n = 31) or chronic (n = 23) infection. The degree of viral suppression and time of initiation of treatment influenced the magnitude of the CD8+ T-cell response. HIV-1-specific CD8+ T cells can increase in number after HAART in subjects treated early after infection who have episodes of transient viremia.
摘要
在感染后早期接受治疗的1型人类免疫缺陷病毒（HIV-1）感染者中，HIV-1特异性CD4+ T细胞功能得以保留。我们研究了高效抗逆转录病毒疗法（HAART）对早期（n = 31）或慢性（n = 23）感染患者中HIV-1特异性CD8+ T细胞频率的影响。病毒抑制程度和开始治疗的时间影响了CD8+ T细胞反应的幅度。在感染后早期接受治疗且有短暂病毒血症发作的受试者中，HAART治疗后HIV-1特异性CD8+ T细胞数量会增加。
相似文献
1
Residual viral replication during antiretroviral therapy boosts human immunodeficiency virus type 1-specific CD8+ T-cell responses in subjects treated early after infection.
J Virol. 2002 Jan;76(1):411-5. doi: 10.1128/jvi.76.1.411-415.2002.
2
Impact of antiretroviral therapy and changes in virus load on human immunodeficiency virus (HIV)-specific T cell responses in primary HIV infection.
J Infect Dis. 2003 Mar 1;187(5):748-57. doi: 10.1086/368333. Epub 2003 Feb 18.
3
Decay kinetics of human immunodeficiency virus-specific CD8+ T cells in peripheral blood after initiation of highly active antiretroviral therapy.
J Virol. 2001 Jul;75(14):6508-16. doi: 10.1128/JVI.75.14.6508-6516.2001.
4
Functional restoration of human immunodeficiency virus and Epstein-Barr virus-specific CD8(+) T cells during highly active antiretroviral therapy is associated with an increase in CD4(+) T cells.
Eur J Immunol. 2002 Apr;32(4):1080-9. doi: 10.1002/1521-4141(200204)32:4<1080::AID-IMMU1080>3.0.CO;2-R.
5
Residual HIV-specific CD4 and CD8 T cell frequencies after prolonged antiretroviral therapy reflect pretreatment plasma virus load.
AIDS. 2002 Nov 22;16(17):2317-22. doi: 10.1097/00002030-200211220-00012.
6
Discordant outcomes following failure of antiretroviral therapy are associated with substantial differences in human immunodeficiency virus-specific cellular immunity.
J Virol. 2003 May;77(10):6041-9. doi: 10.1128/jvi.77.10.6041-6049.2003.
7
Poor lymphoproliferative responses with low proportion of Gag-specific CD8 TEMRA cells in HIV-1-infected patients showing immunological and virological discordance despite prolonged suppression of plasma viremia.
Viral Immunol. 2010 Feb;23(1):49-61. doi: 10.1089/vim.2009.0069.
8
Human immunodeficiency virus type I-specific CD8+ T cell subset abnormalities in chronic infection persist through effective antiretroviral therapy.
BMC Infect Dis. 2010 May 25;10:129. doi: 10.1186/1471-2334-10-129.
9
Immune reconstitution and viral stimulation are required to restore HIV-specific CD8 T cell responses following advanced infection.
J Clin Immunol. 2004 Mar;24(2):115-24. doi: 10.1023/B:JOCI.0000019776.38147.e6.
10
CD38 expression on CD8 T lymphocytes as a marker of residual virus replication in chronically HIV-infected patients receiving antiretroviral therapy.
AIDS Res Hum Retroviruses. 2004 Feb;20(2):227-33. doi: 10.1089/088922204773004950.
引用本文的文献
1
Persistent Low-level Viremia While on Antiretroviral Therapy Is an Independent Risk Factor for Virologic Failure.
Clin Infect Dis. 2019 Nov 27;69(12):2145-2152. doi: 10.1093/cid/ciz129.
2
Sustained and transient oscillations and chaos induced by delayed antiviral immune response in an immunosuppressive infection model.
J Math Biol. 2014 Jan;68(1-2):477-503. doi: 10.1007/s00285-012-0639-1. Epub 2013 Jan 11.
3
Influence of episodes of intermittent viremia ("blips") on immune responses and viral load rebound in successfully treated HIV-infected patients.
AIDS Res Hum Retroviruses. 2013 Jan;29(1):68-76. doi: 10.1089/AID.2012.0145. Epub 2012 Dec 16.
4
Characterization of peripheral and mucosal immune responses in rhesus macaques on long-term tenofovir and emtricitabine combination antiretroviral therapy.
J Acquir Immune Defic Syndr. 2012 Dec 1;61(4):425-35. doi: 10.1097/QAI.0b013e318266be53.
5
Persistence of genital tract T cell responses in HIV-infected women on highly active antiretroviral therapy.
J Virol. 2010 Oct;84(20):10765-72. doi: 10.1128/JVI.00518-10. Epub 2010 Aug 4.
6
Dynamics of intermittent viremia during highly active antiretroviral therapy in patients who initiate therapy during chronic versus acute and early human immunodeficiency virus type 1 infection.
J Virol. 2004 Oct;78(19):10566-73. doi: 10.1128/JVI.78.19.10566-10573.2004.
7
CD8+-cell-mediated suppression of virulent simian immunodeficiency virus during tenofovir treatment.
J Virol. 2004 May;78(10):5324-37. doi: 10.1128/jvi.78.10.5324-5337.2004.
8
Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment.
J Virol. 2003 Apr;77(8):4911-27. doi: 10.1128/jvi.77.8.4911-4927.2003.
9
Boosting immunity by antiviral drug therapy: a simple relationship among timing, efficacy, and success.
Proc Natl Acad Sci U S A. 2003 Feb 18;100(4):1855-60. doi: 10.1073/pnas.0337483100. Epub 2003 Feb 6.
本文引用的文献
1
Skewed maturation of memory HIV-specific CD8 T lymphocytes.
Nature. 2001 Mar 1;410(6824):106-11. doi: 10.1038/35065118.
2
High viral burden in the presence of major HIV-specific CD8(+) T cell expansions: evidence for impaired CTL effector function.
Eur J Immunol. 2001 Mar;31(3):677-86. doi: 10.1002/1521-4141(200103)31:3<677::aid-immu677>3.0.co;2-m.
3
Decay of cell-associated HIV-1 DNA correlates with residual replication in patients treated during acute HIV-1 infection.
AIDS. 2000 Dec 22;14(18):2805-12. doi: 10.1097/00002030-200012220-00001.
4
Cellular immune responses and viral diversity in individuals treated during acute and early HIV-1 infection.
J Exp Med. 2001 Jan 15;193(2):169-80. doi: 10.1084/jem.193.2.169.
5
Reduction in CD8+ cell noncytotoxic anti-HIV activity in individuals receiving highly active antiretroviral therapy during primary infection.
Proc Natl Acad Sci U S A. 2001 Jan 16;98(2):597-602. doi: 10.1073/pnas.98.2.597. Epub 2001 Jan 2.
6
Functionally inert HIV-specific cytotoxic T lymphocytes do not play a major role in chronically infected adults and children.
J Exp Med. 2000 Dec 18;192(12):1819-32. doi: 10.1084/jem.192.12.1819.
7
The role of CD4+ T cell help and CD40 ligand in the in vitro expansion of HIV-1-specific memory cytotoxic CD8+ T cell responses.
J Immunol. 2000 Dec 1;165(11):6133-41. doi: 10.4049/jimmunol.165.11.6133.
8
An antigenic threshold for maintaining human immunodeficiency virus type 1-specific cytotoxic T lymphocytes.
Mol Med. 2000 Sep;6(9):803-9.
9
Impaired function of circulating HIV-specific CD8(+) T cells in chronic human immunodeficiency virus infection.
Blood. 2000 Nov 1;96(9):3094-101.
10
A significant number of human immunodeficiency virus epitope-specific cytotoxic T lymphocytes detected by tetramer binding do not produce gamma interferon.
J Virol. 2000 Nov;74(21):10249-55. doi: 10.1128/jvi.74.21.10249-10255.2000.
Zotero 插件